Related Experiment Videos

Platinum dose-intensity in solid tumors: pharmacological and clinical perspectives

O Pagani¹, C Sessa, F Cavalli

¹Division of Oncology, Ospedale San Giovanni, Bellinzona, Switzerland.

Bulletin Du Cancer

|January 1, 1995

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

A retrospective analysis of phase I and phase I/II investigator-initiated clinical trials conducted by the Swiss Group for Clinical Cancer Research (SAKK).

ESMO open·2025

ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.

ESMO open·2023

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

British journal of cancer·2023

The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective.

ESMO open·2021

Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies.

ESMO open·2021

See all related articles